CMC & Manufacturing

Chemistry, Manufacturing, and Controls(CMC)

The section of a regulatory submission describing a drug's composition, manufacturing process, and quality controls.

Usage Examples

The CMC section included three years of stability data.
FDA issued a CMC-related deficiency letter requesting additional dissolution data.
Post-approval CMC changes were filed as a Prior Approval Supplement.

What is CMC?

Chemistry, Manufacturing, and Controls (CMC) refers to the comprehensive documentation of a drug product's quality attributes, manufacturing processes, and control strategies. CMC information is contained in Module 3 of the CTD and is essential for demonstrating that a drug can be consistently manufactured to meet quality standards.

CMC documentation covers the drug substance (active pharmaceutical ingredient), drug product (finished dosage form), and any excipients. Key elements include specifications, analytical methods, stability data, manufacturing process descriptions, facility information, and container closure systems.

CMC requirements evolve throughout development, from early-phase flexibility to commercial-phase rigor, and post-approval changes require appropriate regulatory filings.

Regulatory Context

This term appears most often in cmc & manufacturing workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside 21 CFR 211, ICH Q8, ICH Q9.

FDAICHHealth Canada

When This Matters

The CMC section included three years of stability data.
FDA issued a CMC-related deficiency letter requesting additional dissolution data.
Post-approval CMC changes were filed as a Prior Approval Supplement.

Common Mistakes

Failing to align CMC change narratives with current CFR/ICH expectations.
Submitting incomplete control strategy documentation.
Separating manufacturing and regulatory review cycles too late in execution.

Related Regulations

21 CFR 211ICH Q8ICH Q9ICH Q10ICH Q12

Frequently Asked Questions

CMC includes drug substance characterization, manufacturing process, controls, specifications, analytical methods, reference standards, container closure, stability data, and for drug product: formulation, process, controls, and finished product specifications.

Early-phase CMC allows flexibility for process optimization. As development progresses, specifications tighten, validation is completed, and commercial manufacturing processes are locked. Post-approval changes require regulatory submissions.

Common deficiencies include incomplete specifications, inadequate method validation, insufficient stability data, unclear process descriptions, missing impurity qualification, and incomplete container closure justification.